small molecule

SIVEXTRO

TEDIZOLID PHOSPHATE

Loss of exclusivityDecember 2030latest FDA-listed patent expiry

CompanyCubist Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	SIVEXTRO
Active ingredient	TEDIZOLID PHOSPHATE
Strength	200MG/VIAL
Dosage form	POWDER
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	June 2014
Marketing status	RX

Listed patents

Patent	Expires	Type
8426389	December 2030	substance, product
9624250	February 2030	substance, product
10442829	February 2030	substance
10065947	February 2030	product
9988406	February 2030	product
7816379	June 2028	substance, product
8420676	February 2028	substance, product

Regulatory exclusivity

Code	Expires
NPP	April 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Cubist Pharmaceuticals